Building on years of expertise
The acquisition comes 14 years after Biogazelle was founded. Since its launch, the company's team has built up vast experience in gene expression analysis. Even more, in 2020, Biogazelle used its technology and equipment to set up a platform – commissioned by the government – to detect the genetic material of the coronavirus in a swab from the nose and throat. Driven by this technological solution for backing COVID testing during the pandemic, the company posted a net profit of over EUR 3 million in 2020.
